Clinical Trial Update: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports on the combination of copanlisib and eribulin in metastatic triple-negative breast cancer in Phase 1/2, with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer
• Unresectable Triple-negative Breast Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-28